HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference ( l lines including PBS-1 cells. Unlik...)

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference

l lines, including PBS-1 cells.

Unlike VERO and MDCK cells, neither CEK cells nor HepaLife's PBS-1 require the need for exogenous proteases, such as Trypsin, therefore eliminating an additional step in manufacturing. However, unlike CEK cells, the PBS-1 cell line is less prone to dangerous contaminating pathogens which are undesirable, disease-causing micro-organisms.

"Our patented PBS-1 cell line successfully produces more influenza virus at higher concentrations than any other tested cell lines, and is able to eliminate a cumbersome manufacturing step involving exogenous proteases," explained Mr. Menzler. "Our cell line is able to remain free of unwanted pathogens, and above all, can out-live and outperform the only other tested cell line that registered any evident influenza virus levels, the CEK."

CEK cells are a primary cell line, typically unable to survive beyond five generations of growth, or 'passages'. HepaLife's PBS-1 cells are a continuous cell line which has already successfully lived through hundreds of passages.

Importantly, scientists have discovered that the PBS-1 cell line may also be suitable for isolating the influenza virus from respiratory samples for diagnostic testing. According to research findings, nineteen blind influenza virus received from human respiratory samples were successfully identified as type-A influenza using PBS-1 cells.

Entitled "High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases," this new data was presented by Kristen Smith from Michigan State University, Department of Animal Science, Molecular Pathogenesis Laboratory, East Lansing, Michigan.

"The success of our patented PBS-1 cell line for influenza vaccine production alongside the parallel success of our patented PICM-19 cell line for development of the world's first-of-its-kind artificial liver device, clearly establishes HepaLife's position as
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
2. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
5. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
6. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetixs AAGP
10. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
11. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

Post Your Comments:

( l lines including PBS-1 cells. Unlik...)HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference,Health